Decrease in the rate of secondary amyloidosis in Turkish children with FMF: are we doing better?

详细信息    查看全文

• 作者：Victoria Akse-?nal (1)
  Erdal Sa? (1)
  Seza Ozen (1)
  Aysin Bakkaloglu (1)
  Nilgun Cakar (2)
  Nesrin Besbas (1)
  Safak Gucer (3)
  
• 关键词：FMF ; Secondary amyloidosis
• 刊名：European Journal of Pediatrics
• 出版年：2010
• 出版时间：August 2010
• 年：2010
• 卷：169
• 期：8
• 页码：971-974
• 全文大小：92KB
• 参考文献：1. Aksentijevich I, Torosyan Y, Samuels J et al (1999) Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. Am J Hum Genet 64:949-62 CrossRef
  2. Bakkaloglu A, Duzova A, Ozen S et al (2004) Influence of Serum Amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/Creactive protein values in patients with familial Mediterranean fever in the Turkish population. J Rheumatol 31:1139-142
  3. Chae JJ, Wood G, Masters SL et al (2006) The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 103(26):9982-987 CrossRef
  4. Gershoni-Baruch R, Brik R, Zacks N et al (2003) The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48:1149-155 CrossRef
  5. Livneh A, Langevitz P (2000) Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol 14:477-98 CrossRef
  6. Martinez FD (2001) The coming-of-age of the hygiene hypothesis. Respir Res 2(3):129-32 CrossRef
  7. Ozen S, Aktay N, Lainka E et al (2009) Disease severity in children and adolescents with familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. Ann Rheum Dis 68:246-48 CrossRef
  8. Ozen S, Karaaslan Y, Ozdemir O et al (1998) Prevalence of juvenile chronic arthritis and familial Mediterranean fever in Turkey: a field study. J Rheumatol 25(12):2445-449
  9. Ozen S, Berdeli A, Türel B et al (2006) Arg753Gln TLR-2 polymorphism in familial Mediterranean fever: linking the environment to the phenotype in a monogenic inflammatory disease. J Rheumatol 33:2498-500
  10. Saatci U, Bakkaloglu A, Ozen S et al (1993) Familial Mediterranean fever and amyloidosis in children. Acta Paediatr 82(8):705-06 CrossRef
  11. Schwabe AD, Peters RS (1974) FMF in Armenians. Analysis of 100 cases. Medicine 53:453-62 CrossRef
  12. Stojanov S, Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17:586-99 CrossRef
  13. Touitou I, Sarkisian T, Medlej-Hashim M et al (2007) International Study Group for Phenotype-Genotype Correlation in Familial Mediterranean Fever. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 56:1706-712 CrossRef
  14. Tunca M, Akar S, Onen F et al (2005) Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84(1):1-1 CrossRef
  15. Yilmaz E, Ozen S, Balci B et al (2001) Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 9:553-55 CrossRef
  
• 作者单位：Victoria Akse-?nal (1)
  Erdal Sa? (1)
  Seza Ozen (1)
  Aysin Bakkaloglu (1)
  Nilgun Cakar (2)
  Nesrin Besbas (1)
  Safak Gucer (3)
  
  1. Department of Pediatrics, Hacettepe University, Ankara, 06100, Turkey
  2. Ministry of Health, Ankara Diskapi Childrens Hospital, Ankara, Turkey
  3. Department of Pediatric Pathology, Hacettepe University, Ankara, Turkey
  

文摘

Familial Mediterranean fever (FMF) is the most common autoinflammatory disease in the world. The most serious complication of FMF is the development of secondary amyloidosis. Besides genetic factors, environment has been implicated in the development of this complication. The main objective of this study is to analyze whether there has been a substantial decrease of secondary amyloidosis in Turkey and possible effective factors. For this purpose, clinical features of the patients diagnosed with secondary amyloidosis between the years 1978 and 1990 were compared with those diagnosed between 2000 and 2009. Severity scores were determined by the use of a scoring system modified for children. Median ages of the group diagnosed between 1978 and 1990 (n--15; 12.1% among a total of 947 renal biopsies) and diagnosed after 2000 (n--9; 2% among a total of 974 renal biopsies) were 12 and 13?years, respectively. There were no significant differences between the two patient groups according to gender, age, age of onset, disease duration, and disease severity. There was, however, a clear decrease in the percentage of biopsies with secondary amyloidosis from 12.1% (1978-990) to 2% (after 2000; p-lt;-.001). Our results have shown that there has been a significant decrease in the rate of secondary amyloidosis in Turkey. The main reason for this decrease is better medical care with increased awareness and treatment of the disease. However, we suggest that the improvement of infectious milieu may possibly have had a positive effect on the course of this monogenic disease, since inflammatory pathways related to innate immunity are deregulated.